Mark Messing

1.9k citations
31 papers · 1.1k · 1 hit paper · h-index 13

Impact in

Papers in

Mark Messing

31 papers receiving 1.1k citations

Mark Messing's Hit Papers

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer 2020 · 366 citations
3660+2+4Years since publication100200300

Peers

Mark Messing
Comparison fields: 5 of 73
  • Reproductive Medicine 360
  • Obstetrics and Gynecology 262
  • Oncology 309
  • Pathology and Forensic Medicine 116
  • Cancer Research 78
Replace Johanna Strehl with:
Johanna Strehl Germany
Joshua Z. Press Canada
Daniela Stramazzotti Italy
P Maxwell United Kingdom
Laura Ardighieri Italy
Fabio Cappuccini United States
Kurosh Rahimi Canada
Najmosama Nikrui United States
Zeina Ghorab Canada
Nobuhiro Takeshima Japan
Mark Messing relative to Johanna Strehl Germany Johanna Strehl's profile →
Citations per field
00.5×3.8×
Johanna Strehl · 1×
Citations per year

Countries citing papers authored by Mark Messing

Since Specialization
Citations

This map shows the geographic impact of Mark Messing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Messing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Messing more than expected).

Fields of papers citing papers by Mark Messing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Messing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Messing. The network helps show where Mark Messing may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Messing, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Messing Line = papers co-authored together Mark Messing links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Hit paper breakdown →
2020366
2 2010171
3 199577
4 199666
5 200960
6 201059
7 200751
8 199436
9 202328
10 198328
11 199323
12 201018
13 199217
14 200211
15 201810
16 19939
17
Atypical glandular cells of undetermined significance and adenocarcinoma in situ: summoning colposcopic expertise?
19969
18 19948
19 20207
20 20047

About Mark Messing

Mark Messing is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Surgery, Oncology and Molecular Biology, having authored 31 papers that have together received 1.1k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (13 papers), Endometrial and Cervical Cancer Treatments (10 papers), Endometriosis Research and Treatment (3 papers), Renal cell carcinoma treatment (2 papers), Cervical Cancer and HPV Research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), HER2/EGFR in Cancer Research (2 papers) and Testicular diseases and treatments (2 papers). The work is most often cited by research in Reproductive Medicine (360 citations), Obstetrics and Gynecology (262 citations), Oncology (309 citations), Pathology and Forensic Medicine (116 citations) and Cancer Research (78 citations). Mark Messing has collaborated with scholars based in United States, Spain and Australia. Frequent co-authors include Kenneth C. Hancock, Joanne Lager, Marcia S. Brose, Danny Rischin, Carol Aghajanian, Allen Lee Cohn, Matthew H. Taylor, Michael Friedländer, Vicky Makker and Emmett V. Schmidt. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Annals of Oncology, Neuro-Oncology and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact